BlueLight Therapeutics
BlueLight Therapeutics develops novel therapeutic molecules for challenging drug targets using a proprietary platform.
Founded
2000BlueLight Therapeutics develops novel therapeutic molecules for challenging drug targets using a proprietary platform.
Founded with a mission to address challenging drug targets, BlueLight Therapeutics leverages a proprietary structure-based platform to discover and develop novel small molecules. The company focuses on creating therapeutic solutions for difficult-to-drug targets, aiming to bring innovative treatments to market. Their expertise spans across a broad range of target classes, driven by a passionate and experienced team dedicated to advancing the field of drug discovery.
Notable figures affiliated with BlueLight Therapeutics include experts in structural assays and drug development, though specific names are not provided. The company has made significant strides in the biotech industry, marked by its unique approach and proprietary technology. BlueLight Therapeutics' impact is reflected in its potential to transform therapeutic strategies for high-value, complex drug targets, contributing to advancements in medical treatments and patient care.
Companies similar to BlueLight Therapeutics include MapLight Therapeutics, Ventus Therapeutics, Septerna and Ensem Therapeutics.
BlueLight Therapeutics was founded in 2000.
BlueLight Therapeutics' headquarters is located in Burlingame, CA, US.
BlueLight Therapeutics' most recent funding round was for $20M (USD) in September 2018.
As of Sep 10, 2018, BlueLight Therapeutics has disclosed funding of $46.6M (USD). Undisclosed round amounts are excluded.
BlueLight Therapeutics has 30 employees as of Feb 4, 2024.
Ensem Therapeutics
ensemtx.com
